Edward Tenthoff
Stock Analyst at Piper Sandler
(2.26)
# 2,726
Out of 4,984 analysts
178
Total ratings
40.94%
Success rate
-2.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $2.53 | +374.31% | 2 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $304 → $449 | $447.71 | +0.29% | 14 | Aug 1, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $5.52 | +171.74% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $2.29 | +118.34% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $62.63 | +67.65% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.90 | +122.87% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $2.02 | +247.39% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $7.49 | +20.16% | 4 | May 29, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.49 | +86.92% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.50 | +302.90% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $13.68 | +250.88% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.69 | +52.96% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $34.90 | +123.50% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $9.90 | +203.03% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $31.15 | +44.46% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $25.81 | +167.34% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $10.02 | +548.70% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.30 | +455.56% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $3.87 | +416.80% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.50 | +100.67% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.73 | +310.17% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $6.80 | +135.29% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.01 | +494.06% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.93 | +159.07% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $50.78 | +10.28% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $18.71 | +1,225.85% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.36 | +2,578.57% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $17.97 | +901.67% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $15.29 | +187.86% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.11 | +420.39% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.91 | +34,094,140.84% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $728.13 | -51.38% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.69 | +7,911.87% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $386.96 | -16.53% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $40.35 | -10.78% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $0.96 | +2,500.92% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.69 | +8,773.64% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.41 | +335,014.13% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $597.51 | - | 11 | Feb 13, 2017 |
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $2.53
Upside: +374.31%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $304 → $449
Current: $447.71
Upside: +0.29%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $5.52
Upside: +171.74%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $2.29
Upside: +118.34%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $62.63
Upside: +67.65%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.90
Upside: +122.87%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $2.02
Upside: +247.39%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $7.49
Upside: +20.16%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.49
Upside: +86.92%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.50
Upside: +302.90%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $13.68
Upside: +250.88%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.69
Upside: +52.96%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $34.90
Upside: +123.50%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $9.90
Upside: +203.03%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $31.15
Upside: +44.46%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $25.81
Upside: +167.34%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $10.02
Upside: +548.70%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $6.30
Upside: +455.56%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $3.87
Upside: +416.80%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.50
Upside: +100.67%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.73
Upside: +310.17%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $6.80
Upside: +135.29%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.01
Upside: +494.06%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.93
Upside: +159.07%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $50.78
Upside: +10.28%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $18.71
Upside: +1,225.85%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.36
Upside: +2,578.57%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $17.97
Upside: +901.67%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $15.29
Upside: +187.86%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.11
Upside: +420.39%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.91
Upside: +34,094,140.84%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $728.13
Upside: -51.38%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.69
Upside: +7,911.87%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $386.96
Upside: -16.53%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $40.35
Upside: -10.78%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $0.96
Upside: +2,500.92%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.69
Upside: +8,773.64%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.41
Upside: +335,014.13%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $597.51
Upside: -